CanSino Biologics (HKG:6185, SHA:688185) will receive a further $17 million grant from Bill & Melinda Gates Foundation for the continued development of the recombinant poliomyelitis vaccine (CS-2036), a Wednesday bourse filing said.
The Chinese biotechnology firm had initially obtained $2 million of funding from the foundation in October 2023.
The further development included clinical research, process development and scale-up, and the development of CS-2036 component combined vaccine candidates
Shares of the company closed over 8% lower on Wednesday.
Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。